达格列净对肾脏和心血管保护效应研究进展

doi:10.20047/j.issn1673-7210.2022.36.12

Abstract
Figure/Table
References (36)
Related Citation (15)

Download: PDF (486 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Dapagliflozin, sodium-glucose cotransporter 2 inhibitor, a new type of hypoglycemic agent. Dapagliflozin effectively inhibits the renal tubule SGLT2 receptor, reduces the renal tubule glucose reabsorption, and promotes the glucose excretion from urine, and reduces blood glucose levels in a non-insulin-dependent manner. In addition to lowering blood glucose, Dapagliflozin also has osmotic diuretic, weight loss, antihypertensive, lipid lowering, urate lowering, and other effects, and plays a protective effect of heart and kidney through anti-fibrosis, anti-inflammatory, antioxidant stress, improving mitochondrial function, regulating autophagy, and restoring tube-ball balance and so on. This article summarizes the protective effect and possible mechanisms of Dapagliflozin on kidney and cardiovascular, in order to provide reference for the clinical application of the drug.

Key words： Dapagliflozin Kidney Cardiovascular Protective effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wenjing ZHENG Wenfei LI Shengnan LIU Qian

Cite this article:

WANG Wenjing ZHENG Wenfei LI Shengnan LIU Qian. Research progress on the protective effect of Dapagliflozin on kidney and cardiovascular[J]. 中国医药导报, 2022, 19(36): 62-65.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.36.12 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I36/62

[1] Pang ZD，Wang Y，Wang XJ，et al. KCa3.1 channel mediates inflammatory signaling of pancreatic beta cells and progression of type 2 diabetes mellitus [J]. FASEB J，2019，33（12）：14760-14771.
[2] 刘瑶，金立军.达格列净在心力衰竭中的应用及作用机制的研究进展[J].实用心脑肺血管病杂志，2021，29（11）：5-9.
[3] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南（2021年版）[J].中华糖尿病杂志，2021， 13（8）：762-784.
[4] 邹泰基，彭涛.达格列净治疗2型糖尿病的研究进展[J].西北民族大学学报（自然科学版），2021，42（2）：46-50.
[5] 马静.达格列净治疗2型糖尿病患者的应用进展[J].现代诊断与治疗，2021，32（16）：2544-2545，2589.
[6] 刘畅，郭明艳，邵丽颖.达格列净在2型糖尿病中的临床应用及不良反应研究进展[J].慢性病学杂志，2021，22（10）：1485-1488，1493.
[7] 杨洋，魏鹏翔，张村，等.达格列净联合常规降糖药治疗糖尿病有效性和安全性的Meta分析[J].中国循证医学杂志，2019，19（12）：1436-1445.
[8] Mosenzon O，Wiviott SD，Cahn A，et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes：an analysis from the DECLARE-TIMI 58 randomised trial [J]. Lancet Diabetes Endocrinol，2019，7（8）：606-617.
[9] Wanner C，Inzucchi SE，Lachin JM，et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes [J]. N Engl J Med，2016，375（4）：323-334.
[10] Heerspink H，Stefansson BV，Correa-Rotter R，et al. Dapagliflozin in Patients with Chronic Kidney Disease[J]. N Engl J Med，2020，383（15）：1436-1446.
[11] Wheeler DC，Stefansson BV，Jongs N，et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease：a prespecified analysis from the DAPA-CKD trial [J]. Lancet Diabetes Endocrinol，2021，9（1）：22-31.
[12] Wheeler DC，Stefansson BV，Batiushin M，et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease（DAPA-CKD）trial：baseline characteristics [J]. Nephrol Dial Transplant，2020，35（10）：1700-1711.
[13] Zelniker TA，Wiviott SD，Raz I，et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes：a systematic review and meta-analysis of cardiovascular outcome trials [J]. Lancet，2019，393（10166）：31-39.
[14] 付强，刘丽秋.达格列净对早期糖尿病肾病的保护作用及其可能机制[J].中国临床药学杂志，2021，30（5）：330- 334.
[15] 杨秋旻，李佳荫，张艳，等.达格列净对糖尿病小鼠肾保护作用及机制研究[J].临床军医杂志，2021，49（10）：1127- 1132.
[16] Yao D，Wang S，Wang M，et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1receptor for advanced glycation end productsnuclear factor kappa B signaling pathway [J]. Mol Med Rep，2018，18（4）：3625-3630.
[17] 丁庭庭.达格列净对糖尿病肾病保护作用的机制研究[D].合肥：安徽医科大学，2021：62.
[18] 陈利佳，毛楠.SGLT2抑制剂通过调控TLR通路诱导糖尿病肾病大鼠足细胞自噬的机制研究[J].免疫学杂志，2021，37（10）：868-874.
[19] Vallon V，Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia：the pleiotropic effects of SGLT2 inhibition [J]. Diabetologia，2017，60（2）：215-225.
[20] Fioretto P，Zambon A，Rossato M，et al. SGLT2 Inhibitors and the Diabetic Kidney [J]. Diabetes Care，2016，39 Suppl 2：S165-S171.
[21] Alicic RZ，Neumiller JJ，Johnson EJ，et al. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease [J]. Diabetes，2019，68（2）：248-257.
[22] Vrolijk MF，Van EH，Opperhuizen A，et al. Haemodynamic effects of the flavonoid quercetin in rats revisited [J]. Br J Pharmacol，2020，177（8）：1841-1852.
[23] 纪立农，郭立新，郭晓蕙，等.钠-葡萄糖共转运蛋白2（SGLT2）抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志，2016，24（10）：865-870.
[24] 盛晓生，曹聪聪，蒋李珍，等.SGLT2抑制剂达格列净在心血管疾病中的应用进展[J].中国现代医生，2021，59（24）：188-192.
[25] McMurray J，DeMets DL，Inzucchi SE，et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure（DAPA-HF）trial：baseline characteristics [J]. Eur J Heart Fail，2019，21（11）：1402-1411.
[26] Packer M. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion [J]. Cardiovasc Diabetol，2019，18（1）：129.
[27] 梁志山，许志盟，吉庆伟.钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭循证证据与机制的研究进展[J].中国临床新医学，2021，14（6）：554-558.
[28] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2020年版）[J].中华糖尿病杂志，2021，13（4）：317-411.
[29] European Society of Cardiology. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [S]. DOI：10.1093/eurheartj/ehab368.
[30] Heidenreich PA，Bozkurt B，Aguilar D. 2022 AHA/ACC/ HFSA Guideline for the Management of Heart Failure： Executive Summary：A Report of the American College of Cardiology/American Heart Association [J]. J Am Coll Cardiol，2022，79（17）：1757-1780.
[31] Lytvyn Y，Bjornstad P，Udell JA，et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure：Potential Mechanisms，Clinical Applications，and Summary of Clinical Trials [J]. Circulation，2017，136（17）：1643-1658.
[32] Prattichizzo F，De Nigris V，Micheloni S，et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors：Is low-grade inflammation the neglected component? [J]. Diabetes Obes Metab，2018， 20（11）：2515-2522.
[33] Li FF，Gao G，Li Q，et al. Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus [J]. J Diabetes Res，2016，2016：5347262.
[34] Leng W，Ouyang X，Lei X，et al. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice [J]. Mediators Inflamm，2016，2016， 6305735.
[35] Joshi SS，Singh T，Newby DE，et al. Sodium-glucose co- transporter 2 inhibitor therapy：mechanisms of action in heart failure [J]. Heart，2021，107（13）：1032-1038.
[36] Uthman L，Baartscheer A，Bleijlevens B，et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts：inhibition of Na+/H+ exchanger，lowering of cytosolic Na+ and vasodilation [J]. Diabetologia，2018，61（3）：722-726.